Literature DB >> 22804246

p53 is an important regulator of CCL2 gene expression.

X Tang1, M Asano, A O'Reilly, A Farquhar, Y Yang, S Amar.   

Abstract

The p53 protein is a sequence-specific DNA-binding factor that regulates inflammatory genes such as CCL2/MCP-1 that may play a role in various diseases. A recent study has indicated that the knockdown of human p53 leads to a strong negative regulation of CCL2 induction. We are therefore interested in how p53 regulates CCL2 gene expression. In the following study, our findings indicate that UV-induced p53 accumulation in mouse macrophages significantly decreases LPS-induced CCL2 production, and that p53 binds to CCL2 5'UTR in the region (16-35). We also found that a p53 domain (p53pep170) mimics full length p53 to down-regulate CCL2 promoter activity. Treatment of p53-deficient mouse primary macrophages with synthetic p53pep170 was found to decrease LPS-induced production of CCL2 without association with cellular endogenous p53. CCL2 production induced by lentiCLG in human monocytes or mouse primary macrophages was blocked in the presence of p53pep170. Overall, these results demonstrate that p53 or its derived peptide (p53pep170) is an important regulator of CCL2 gene expression via its binding activity, and acts as a novel model for future studies linking p53 and its short peptide to pave the way to possible pharmaceutical intervention of CCL2-mediated inflammatory and cancer diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22804246      PMCID: PMC3786129          DOI: 10.2174/156652412802480844

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  70 in total

Review 1.  The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis.

Authors:  P P Tak; B Bresnihan
Journal:  Arthritis Rheum       Date:  2000-12

Review 2.  Chemokines as novel therapeutic targets in inflammatory diseases.

Authors:  Maureen N Ajuebor; Mark G Swain; Mauro Perretti
Journal:  Biochem Pharmacol       Date:  2002-04-01       Impact factor: 5.858

3.  Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript.

Authors:  Virginie Marcel; Stéphane Perrier; Mustapha Aoubala; Sylvain Ageorges; Michael J Groves; Alexandra Diot; Kenneth Fernandes; Sudhir Tauro; Jean-Christophe Bourdon
Journal:  FEBS Lett       Date:  2010-10-13       Impact factor: 4.124

4.  p53 peptide prevents LITAF-induced TNF-alpha-mediated mouse lung lesions and endotoxic shock.

Authors:  X Tang; A O'Reilly; M Asano; J C Merrill; K K Yokoyama; S Amar
Journal:  Curr Mol Med       Date:  2011-08       Impact factor: 2.222

5.  Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform.

Authors:  Tania L Slatter; Noelyn Hung; Hamish Campbell; Carina Rubio; Reena Mehta; Prudence Renshaw; Gail Williams; Michelle Wilson; Afra Engelmann; Aaron Jeffs; Janice A Royds; Margaret A Baird; Antony W Braithwaite
Journal:  Blood       Date:  2011-03-16       Impact factor: 22.113

6.  Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis.

Authors:  Yuji Yamanishi; David L Boyle; Michael J Pinkoski; Artin Mahboubi; Tesu Lin; Zuoning Han; Nathan J Zvaifler; Douglas R Green; Gary S Firestein
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 7.  The role of tetramerization in p53 function.

Authors:  P Chène
Journal:  Oncogene       Date:  2001-05-10       Impact factor: 9.867

8.  Lipopolysaccharide of Burkholderia cepacia and its unique character to stimulate murine macrophages with relative lack of interleukin-1beta-inducing ability.

Authors:  H Shimomura; M Matsuura; S Saito; Y Hirai; Y Isshiki; K Kawahara
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

9.  Bleomycin sensitivity of mice expressing dominant-negative p53 in the lung epithelium.

Authors:  Sushmita Ghosh; Tamra Mendoza; Luis A Ortiz; Gary W Hoyle; Cesar D Fermin; Arnold R Brody; Mitchell Friedman; Gilbert F Morris
Journal:  Am J Respir Crit Care Med       Date:  2002-09-15       Impact factor: 21.405

10.  Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice.

Authors:  M Schilling; J-K Strecker; W-R Schäbitz; E B Ringelstein; R Kiefer
Journal:  Neuroscience       Date:  2009-04-15       Impact factor: 3.590

View more
  17 in total

Review 1.  Immune surveillance of unhealthy cells by natural killer cells.

Authors:  Alexandre Iannello; David H Raulet
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2013-10-17

Review 2.  The Photomodulation Activity of Metformin Against Oral Microbiome.

Authors:  Shima Afrasiabi; Maryam Pourhajibagher; Abbas Bahador
Journal:  J Lasers Med Sci       Date:  2019-07-06

Review 3.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 4.  Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.

Authors:  Zhiwei Hu; Samira A Brooks; Valérian Dormoy; Chia-Wen Hsu; Hsue-Yin Hsu; Liang-Tzung Lin; Thierry Massfelder; W Kimryn Rathmell; Menghang Xia; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Kalan R Prudhomme; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Leroy Lowe; Lasse Jensen; William H Bisson; Nicole Kleinstreuer
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Authors:  Josephine Walton; Julianna Blagih; Darren Ennis; Elaine Leung; Suzanne Dowson; Malcolm Farquharson; Laura A Tookman; Clare Orange; Dimitris Athineos; Susan Mason; David Stevenson; Karen Blyth; Douglas Strathdee; Frances R Balkwill; Karen Vousden; Michelle Lockley; Iain A McNeish
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

6.  TP53 gain-of-function mutation promotes inflammation in glioblastoma.

Authors:  Seok Won Ham; Hee-Young Jeon; Xiong Jin; Eun-Jung Kim; Jun-Kyum Kim; Yong Jae Shin; Yeri Lee; Se Hoon Kim; Seon Yong Lee; Sunyoung Seo; Min Gi Park; Hye-Mi Kim; Do-Hyun Nam; Hyunggee Kim
Journal:  Cell Death Differ       Date:  2018-05-21       Impact factor: 15.828

7.  The Key Network of mRNAs and miRNAs Regulated by HIF1A in Hypoxic Hepatocellular Carcinoma Cells.

Authors:  Tong Liu; Jing Tang; Xiaoyu Li; Yuan Lin; Yuma Yang; Kai Ma; Zhaoyuan Hui; Hong Ma; Yanyan Qin; Hetian Lei; Yanhui Yang
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

8.  p53 suppresses CCL2-induced subcutaneous tumor xenograft.

Authors:  Xiaoren Tang; Salomon Amar
Journal:  Tumour Biol       Date:  2014-12-11

Review 9.  Oral bacteria and cancer.

Authors:  Sarah E Whitmore; Richard J Lamont
Journal:  PLoS Pathog       Date:  2014-03-27       Impact factor: 6.823

10.  p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells.

Authors:  Alexandre Iannello; Thornton W Thompson; Michele Ardolino; Scott W Lowe; David H Raulet
Journal:  J Exp Med       Date:  2013-09-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.